[시장보고서]세계의 임상 진단 시장(2023-2030년)

세계의 임상 진단 시장(2023-2030년)

Global Clinical Diagnostics Market - 2023-2030

상품코드 : 1316234

리서치사 : DataM Intelligence

발행일 : 2023년 07월

페이지 정보 : 영문 195 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,350

￦ 6,069,000

PDF & Excel (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,850

￦ 6,767,000

PDF & Excel (Multiple User License)

PDF 보고서를 동일 사업장에서 7명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,850

￦ 10,953,000

PDF & Excel (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

시장 개요

세계 임상 진단 시장은 2022년 732억 달러, 2030년에는 1,100억 달러에 달할 것으로 예상됩니다. 세계 임상 진단 시장은 예측 기간(2023-2030년) 동안 5.3%의 CAGR을 기록할 것으로 예상됩니다.

분자 진단 방법은 유전 물질(DNA 또는 RNA)을 분석하여 유전자 변이, 돌연변이 또는 질병과 관련된 특정 바이오마커를 찾습니다. 일반적으로 사용되는 중합 효소 연쇄 반응(PCR)으로 알려진 분자 기술은 특정 DNA 서열을 증폭하고 감지합니다. 유전자 검사, 감염 검사, 암 프로파일링, 유전성 질환의 검출은 모두 분자 진단을 사용합니다.

시장 역학

예측 기간 동안 세계 임상 진단 시장의 성장을 촉진하는 주요 업체들의 활약

2023년 2월, 로슈는 연구개발 노력을 더욱 강화하기 위해 얀센 바이오텍(Janssen Biotech Inc.)과의 제휴를 확대하여 표적 치료의 동반 진단을 개발할 것이라고 발표했습니다.

이번 파트너십 확대로 로슈와 얀센은 면역조직화학(IHC), 디지털 병리학, 차세대 염기서열 분석, 중합효소 연쇄반응, 면역 분석 등 정밀의료 분야의 동반자적 진단 프로젝트에서 더 많은 협력 옵션을 제공할 수 있게 되었습니다.

기술의 발전으로 세계 임상 진단 시장에 성장 기회 제공

2023년 3월, 타타 그룹의 새로운 헬스케어 회사인 타타 메디컬 앤 진단(Tata Medical and Diagnostics, 이하 타타 MD)은 현지에서 개발된 Tata MD CHECK를 표준화하고 새로운 감염률을 낮추기 위해 첸나이에 본사를 둔 Anderson Diagnostics &Labs(ADL)와 제휴했습니다.

"Made-in-India" Tata MD CHECK 진단 키트는 ADL의 임상 전문가들과의 협력을 통해 빠르게 확장할 수 있으며, ADL은 이미 Feluda CRISPR Platform을 기반으로 한 DGCA 승인 진단 솔루션으로 1만 건 이상의 COVID-19 검사를 성공적으로 수행한 바 있습니다. "10,000개 이상의 샘플을 테스트하고 검증한 결과, 이 기술은 최첨단이며 세계 최고 수준이라고 확신한다"고 말했습니다.

COVID-19 영향 분석

COVID-19 전염병은 임상 진단 시장에 큰 영향을 미쳤습니다. 임상 진단 연구 및 개발은 COVID-19 팬데믹으로 인해 COVID-19 검출에 특화된 새로운 진단 분석법, 기술 및 플랫폼이 빠르게 개발되었습니다. 이러한 개발은 전염병과 싸우는 데 도움이 되고 있으며, 임상 진단 업계 전체에 도움이 되는 새로운 아이디어와 정보를 창출하고 있습니다.

러시아-우크라이나 분쟁 분석

러시아-우크라이나 분쟁이 임상 진단 시장에 미치는 영향은 복잡하고 다면적입니다. 인프라, 자원, 지식의 부족으로 인해 분쟁이 발생한 지역에서는 새로운 진단 기술에 대한 접근이 어려워질 수 있습니다. 분자진단 및 영상진단 기술을 포함한 최첨단 진단 기술의 사용과 이용이 제한될 수 있으며, 이는 진단 서비스의 정확성과 무결성에 영향을 미칠 수 있습니다.

영문목차

Market Overview

The global clinical diagnostics market reached US$ 73.2 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 110.0 billion by 2030. The global clinical diagnostics market is expected to exhibit a CAGR of 5.3% during the forecast period (2023-2030).

In molecular diagnostic methods, genetic material (DNA or RNA) is analyzed to find genetic variants, mutations, or particular biomarkers linked to diseases. The commonly used molecular technique known as polymerase chain reaction (PCR) amplifies and detects particular DNA sequences. Genetic testing, infectious disease testing, cancer profiling, and the detection of genetic diseases all use molecular diagnostics.

Market Dynamics

Active Major Players are Boosting the Global Clinical Diagnostics Market Growth During the Forecast Period

In February 2023, In order to further boost its research and innovation efforts, Roche stated that it had increased its partnership with Janssen Biotech Inc. to develop companion diagnostics for targeted treatments.

With the new, enlarged partnership, Roche and Janssen will have more options to work together on companion diagnostics projects in the area of precision medicine, including immunohistochemistry (IHC), digital pathology, next-generation sequencing, polymerase chain reaction, and immunoassays.

Technological Advancements Provide Global Clinical Diagnostics Market Growth Opportunities

In March 2023, In an effort to standardize the locally developed Tata MD CHECK and reduce the rate of new infections, Tata Medical and Diagnostics (Tata MD), a new healthcare company from the Tata family, has partnered with Chennai-based Anderson Diagnostics & Labs (ADL).

The "Made-in-India" Tata MD CHECK diagnostic kit can now be scaled up quickly due to the collaboration with ADL's clinical experts. ADL has already successfully completed over 10,000 COVID tests using this new, DGCA-approved, novel diagnostic solution based on the Feluda CRISPR Platform. "After testing and validating more than 10,000 samples, we believe this technology to be both cutting edge and on par with the best in the world.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the clinical diagnostics market. Clinical diagnostics research and development have been sparked by the COVID-19 pandemic. New diagnostic assays, technologies, and platforms made specifically for the detection of COVID-19 have developed quickly. These developments have aided in the fight against the pandemic and have generated new ideas and information that will help the clinical diagnostics industry as a whole.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the clinical diagnostics market is complex and multifaceted. Due to a lack of infrastructure, resources, and knowledge, access to new diagnostic technology may be difficult in conflict-affected areas. The use and accessibility of cutting-edge diagnostic techniques, including molecular diagnostics or imaging technology, may be constrained, which could have an impact on the accuracy and thoroughness of diagnostic services.

Segment Analysis

The global clinical diagnostics market is segmented based on test, product, end-user, and region.

The Lipid Panel Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The lipid panel segment accounted for the highest market stake accounting for approximately 32.3% of the clinical diagnostics market in 2022. The lipid panel measures different lipids (fats) and the characteristics that go along with them in the bloodstream. It offers significant details on a person's lipid profile and cholesterol levels, which are essential markers of cardiovascular health.

Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol are both measured as well as the overall amount of cholesterol in the blood. Healthcare providers can determine a patient's risk for cardiovascular disease based on the findings of a lipid panel test and offer medication, lifestyle changes, or other therapies as necessary.

Geographical Analysis

Asia Pacific is Expected to hold Around 25.7% Share of this Market due to Increasing Collaborations and Partnerships Among the Key Players, and Advancement in Clinical Diagnostics

Asia Pacific is expected to hold around 25.7% share of this market. For instance, in May 2023, a high-end diagnostic solutions provider called Core Diagnostics, with its headquarters in Gurugram, announced the opening of a new satellite facility in East Delhi's Hargobind Enclave. With this strategic growth, the company hopes to increase its testing capabilities and give patients and healthcare professionals better access to high-quality diagnostic services.

The satellite lab is a crucial component of Core Diagnostics' strategic expansion plan, which aims to increase the company's testing capacity and satisfy the increasing demand for quality and timely diagnostic services. By bringing superior diagnostic options closer to healthcare professionals and patients, they are able to give them the precise information they need to make prompt medical decisions.

Competitive Landscape

The major global players in the market include: Abbott Laboratories, Becton, Dickinson and Company, BioMerieux, Bio-Rad Laboratories Inc., Danaher Corporation, Siemens AG, Hologic Inc., Qiagen NV, F. Hoffmann-La Roche AG, Thermo Fisher Scientific among others.

Why Purchase the Report?

To visualize the global clinical diagnostics market segmentation based on the test, product, end-user, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of clinical diagnostics market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global clinical diagnostics market report would provide approximately 61 tables, 61 figures, and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Test
3.2. Snippet by Product
3.3. Snippet by End-user
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising burden of disease
- 4.1.2. Restraints
  - 4.1.2.1. Stringent regulatory requirements
- 4.1.3. Opportunity
  - 4.1.3.1. Technological advancements
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Test

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
- 9.1.2. Market Attractiveness Index, By Test
9.2. Lipid Panel*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Liver Panel
9.4. Renal Panel
9.5. Complete Blood Count
9.6. Electrolyte Testing
9.7. Infectious Disease Testing
9.8. Other Tests

10. By Product

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.1.2. Market Attractiveness Index, By Product
10.2. Instruments*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Reagents
10.4. Others

11. By End-user

11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
11.1.2. Market Attractiveness Index, By End-user

11.2. Hospital Laboratory*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Diagnostic Laboratory
11.4. Point-of-care Testing
11.5. Others

12. By Region

12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 12.1.2. Market Attractiveness Index, By Region
12.2. North America
- 12.2.1. Introduction
- 12.2.2. Key Region-Specific Dynamics
- 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
- 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.2.6.1. U.S.
  - 12.2.6.2. Canada
  - 12.2.6.3. Mexico
12.3. Europe
- 12.3.1. Introduction
- 12.3.2. Key Region-Specific Dynamics
- 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
- 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.3.6.1. Germany
  - 12.3.6.2. U.K.
  - 12.3.6.3. France
  - 12.3.6.4. Italy
  - 12.3.6.5. Spain
  - 12.3.6.6. Rest of Europe
12.4. South America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
- 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.4.6.1. Brazil
  - 12.4.6.2. Argentina
  - 12.4.6.3. Rest of South America
12.5. Asia-Pacific
- 12.5.1. Introduction
- 12.5.2. Key Region-Specific Dynamics
- 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
- 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.5.6.1. China
  - 12.5.6.2. India
  - 12.5.6.3. Japan
  - 12.5.6.4. Australia
  - 12.5.6.5. Rest of Asia-Pacific
12.6. Middle East and Africa
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
- 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

13. Competitive Landscape

13.1. Competitive Scenario
13.2. Product Benchmarking
13.3. Company Share Analysis
13.4. Key Developments and Strategies

14. Company Profiles

14.1. Abbott Laboratories*
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Financial Overview
- 14.1.4. Key Developments
14.2. Becton, Dickinson and Company
14.3. BioMerieux
14.4. Bio-Rad Laboratories Inc.
14.5. Danaher Corporation
14.6. Siemens AG
14.7. Hologic Inc.
14.8. Qiagen NV
14.9. F. Hoffmann-La Roche AG
14.10. Thermo Fisher Scientific

LIST NOT EXHAUSTIVE

15. Appendix

15.1. About Us and Services
15.2. Contact Us

한글목차

시장 개요

시장 역학

예측 기간 동안 세계 임상 진단 시장의 성장을 촉진하는 주요 업체들의 활약

기술의 발전으로 세계 임상 진단 시장에 성장 기회 제공

COVID-19 영향 분석

러시아-우크라이나 분쟁 분석

목차

제1장 조사 방법과 조사 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

제5장 산업 분석

제6장 COVID-19 분석

제7장 러시아·우크라이나 전쟁 분석

제8장 인공지능 분석

제9장 검사별

제10장 제품별

제11장 최종사용자별

제12장 지역별

제13장 경쟁 상황

제14장 기업 개요

제15장 부록